Global Long-acting Monoclonal Antibodies Market Size Study, By Source Type (Murine, Chimeric, Humanized, Human) By Indication (Cancer, Autoimmune Disease, Inflammatory Disease, Infectious Disease, Others) By End-User (Hospital Pharmacies, Drug Store, Reta

Global Long-acting Monoclonal Antibodies Market Size Study, By Source Type (Murine, Chimeric, Humanized, Human) By Indication (Cancer, Autoimmune Disease, Inflammatory Disease, Infectious Disease, Others) By End-User (Hospital Pharmacies, Drug Store, Retail Pharmacies, E-Commerce) and regional forecasts 2022-2028

Global Long-acting Monoclonal Antibodies Market is valued approximately USD xx Billion in 2021 and is anticipated to grow with a healthy growth rate of more than xx % over the forecast period 2022-2028. Long-acting Monoclonal antibodies (mAbs or moAbs) are antibodies created by cloning a single white blood cell. Every subsequent antibody generated in this manner may be traced back to a single parent cell. Monoclonal antibodies can only attach to the same epitope and have monovalent affinity (the part of an antigen that is recognised by the antibody). Growing prevalence of chronic diseases, surfacing sedentary lifestyle and use of MABs in the treatment of Covid-19 has driven the long-acting monoclonal antibodies market. For Instance: Eli Lilly discovers etesevimab, a monoclonal antibody that targets the receptor binding region of the SARS-CoV-2 surface spike protein. Also, on-going advanced research and development is most likely to boost the overall growth of the Global Long-acting Monoclonal Antibodies Market. However, high cost of mAbs can obstruct the market's expansion over the projection period of 2022-2028.

The key regions considered for the Global Long-acting Monoclonal Antibodies Market study includes Asia Pacific, North America, Europe, Latin America and Rest of the World. US is the leading region across the world. Presence of major key players and leading industries in this region is driving the market growth in the North America. Whereas, Europe is also anticipated to exhibit highest growth rate over the forecast period 2022-2028. The market is expected to grow during the projected period, due to expanding R&D.
Major market player included in this report are:
Eli Lilly
Abbott Laboratories
AstraZeneca plc
Amgen Inc.
Bayer AG
Johnson & Johnson
Pfizer
GlaxoSmithKline Plc.
Merck & Co. Inc.
Novartis
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the Application within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Source Type:
Murine
Chimeric
Humanized
Human

By Indication:
Cancer
Autoimmune Disease
Inflammatory Disease
Infectious Disease
Others
By End-User:
Hospital Pharmacies
Drug Store
Retail Pharmacies
E-commerce

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028

Target Audience of the Global Long-acting Monoclonal Anibodies Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors

Companies Mentioned

Eli Lilly
Abbott Laboratories
AstraZeneca plc
Amgen Inc.
Bayer AG
Johnson & Johnson
Pfizer
GlaxoSmithKline Plc.
Merck & Co. Inc.
Novartis